Rothschild Asset Management Inc. increased its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 2.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,587 shares of the biopharmaceutical company’s stock after acquiring an additional 689 shares during the period. Rothschild Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,370,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. Jennison Associates LLC raised its holdings in Bristol-Myers Squibb by 0.8% during the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after acquiring an additional 178,436 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Legal & General Group Plc raised its holdings in Bristol-Myers Squibb by 4.3% during the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after acquiring an additional 335,795 shares in the last quarter. Finally, Swiss National Bank raised its holdings in Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares in the last quarter. Institutional investors and hedge funds own 68.88% of the company’s stock.

Several analysts recently issued reports on the company. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price on the stock. in a report on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 17th. Credit Suisse Group AG set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $61.84.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/06/rothschild-asset-management-inc-has-1-37-million-position-in-bristol-myers-squibb-company-bmy.html.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) opened at 63.80 on Friday. The firm has a market cap of $104.63 billion, a P/E ratio of 23.30 and a beta of 1.19. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $64.79. The stock has a 50 day moving average price of $61.33 and a 200 day moving average price of $56.59. Bristol-Myers Squibb also saw unusually large options trading activity on Wednesday. Stock investors purchased 37,577 call options on the stock. This represents an increase of approximately 274% compared to the average daily volume of 10,041 call options.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter last year, the business posted $0.69 EPS. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.45%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.